Oluwatoyosi A Onwuemene1, Steven C Grambow2, Chetan B Patel3, Robert J Mentz3, Carmelo A Milano4, Joseph G Rogers3, Ara D Metjian1, Gowthami M Arepally1,5, Thomas L Ortel1,5. 1. Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina. 2. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina. 3. Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina. 4. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 5. Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Abstract
INTRODUCTION: Limited data are available describing indications for and outcomes of therapeutic plasma exchange (TPE) in cardiac transplantation. METHODS: In a retrospective study of patients who underwent cardiac transplantation at Duke University Medical Center from 2010 to 2014, we reviewed 3 TPE treatment patterns: a Single TPE procedure within 24 h of transplant; Multiple TPE procedures initiated within 24 h of transplant; and 1 or more TPE procedures beginning >24 h post-transplant. Primary and secondary outcomes were overall survival (OS) and TPE survival (TS), respectively. RESULTS: Of 313 patients meeting study criteria, 109 (35%) underwent TPE. TPE was initiated in 82 patients within 24 h, 40 (37%) receiving a single procedure (Single TPE), and 42 (38%) multiple procedures (Multiple TPE). Twenty-seven (25%) began TPE >24 h after transplant (Delayed TPE). The most common TPE indication was elevated/positive panel reactive or human leukocyte antigen antibodies (32%). With a median follow-up of 49 months, the non-TPE treated and Single TPE cohorts had similar OS (HR 1.08 [CI, 0.54, 2.14], P = .84), while the Multiple and Delayed TPE cohorts had worse OS (HR 2.62 [CI, 1.53, 4.49] and HR 1.98 [CI, 1.02, 3.83], respectively). The Multiple and Delayed TPE cohorts also had worse TS (HR 2.59 [CI, 1.31, 5.14] and HR 3.18 [CI, 1.56, 6.50], respectively). Infection rates did not differ between groups but was independently associated with OS (HR 2.31 [CI, 1.50, 3.54]). CONCLUSIONS: TPE is an important therapeutic modality in cardiac transplant patients. Prospective studies are needed to better define TPE's different roles in this patient population.
INTRODUCTION: Limited data are available describing indications for and outcomes of therapeutic plasma exchange (TPE) in cardiac transplantation. METHODS: In a retrospective study of patients who underwent cardiac transplantation at Duke University Medical Center from 2010 to 2014, we reviewed 3 TPE treatment patterns: a Single TPE procedure within 24 h of transplant; Multiple TPE procedures initiated within 24 h of transplant; and 1 or more TPE procedures beginning >24 h post-transplant. Primary and secondary outcomes were overall survival (OS) and TPE survival (TS), respectively. RESULTS: Of 313 patients meeting study criteria, 109 (35%) underwent TPE. TPE was initiated in 82 patients within 24 h, 40 (37%) receiving a single procedure (Single TPE), and 42 (38%) multiple procedures (Multiple TPE). Twenty-seven (25%) began TPE >24 h after transplant (Delayed TPE). The most common TPE indication was elevated/positive panel reactive or human leukocyte antigen antibodies (32%). With a median follow-up of 49 months, the non-TPE treated and Single TPE cohorts had similar OS (HR 1.08 [CI, 0.54, 2.14], P = .84), while the Multiple and Delayed TPE cohorts had worse OS (HR 2.62 [CI, 1.53, 4.49] and HR 1.98 [CI, 1.02, 3.83], respectively). The Multiple and Delayed TPE cohorts also had worse TS (HR 2.59 [CI, 1.31, 5.14] and HR 3.18 [CI, 1.56, 6.50], respectively). Infection rates did not differ between groups but was independently associated with OS (HR 2.31 [CI, 1.50, 3.54]). CONCLUSIONS: TPE is an important therapeutic modality in cardiac transplant patients. Prospective studies are needed to better define TPE's different roles in this patient population.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Elizabeth Sarmiento; Pablo Diez; Mauricio Arraya; Maria Jaramillo; Leticia Calahorra; Juan Fernandez-Yañez; Jesus Palomo; Iago Sousa; Javier Hortal; Jose Barrio; Roberto Alonso; Patricia Muñoz; Joaquin Navarro; Jose Vicario; Eduardo Fernandez-Cruz; Javier Carbone Journal: Transpl Infect Dis Date: 2016-10-25 Impact factor: 2.228
Authors: Michael M Koerner; Aly El-Banayosy; Uwe Schulz; Mohamad Zeriouh; Reiner Koerfer; Gero Tenderich; Ali Ghodsizad Journal: Heart Surg Forum Date: 2015-12-14 Impact factor: 0.676
Authors: Maria G Crespo-Leiro; Alberto Veiga-Barreiro; Nieves Doménech; Maria J Paniagua; Pablo Piñón; Margarita González-Cuesta; Eduardo Vázquez-Martul; Consuelo Ramirez; Jose J Cuenca; Alfonso Castro-Beiras Journal: Am J Transplant Date: 2005-10 Impact factor: 8.086
Authors: Lois U Nwakanma; Jason A Williams; Eric S Weiss; Stuart D Russell; William A Baumgartner; John V Conte Journal: Ann Thorac Surg Date: 2007-11 Impact factor: 4.330
Authors: B F Uretsky; S Murali; P S Reddy; B Rabin; A Lee; B P Griffith; R L Hardesty; A Trento; H T Bahnson Journal: Circulation Date: 1987-10 Impact factor: 29.690